ReviewDiabetes/metabolism research and reviews2026
Illuminating Glucose: How to Unveil Organ-Specific Insulin Resistance and Guide Metabolic Strategies in Diabetes.
Review in Diabetes/metabolism research and reviews, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A Four-Week Treatment With Dapagliflozin Is Associated With a Reduction in Insulin-Stimulated Renal Cortical Glucose Uptake: A Post Hoc Analysis From a Pilot Study.Diabetes, obesity & metabolism · 2026Trial
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Recent evidence has shown that muscle insulin resistance is not the only factor contributing to type 2 diabetes (T2D). Organ-specific insulin resistance is increasingly recognised as a significant contributor to the metabolic changes that lead to hyperglycemia, although the precise extent of its impact remains unclear. The qualitative and quantitative aspects of regional insulin-resistance in determining whole body insulin resistance and glucose uptake can be explored through positron emission tomography (PET) combined with computerised tomography images, using specific radio tracers like 2-deoxy-2-[18F]fluoro-D-glucose ([18F]FDG). This approach provides new insight into organ-specific glucose uptake allowing the visualisation of glucose metabolism. This review article seeks to highlight key findings from dynamic imaging, in terms of glucose uptake, focussing on the specific compartments (muscle, liver, adipose organ, heart, kidney and brain) in different metabolic conditions, such as insulin resistance and T2D, and during metabolic treatment. In essence, mapping these distinct organ contributions in the orchestra of glucose metabolism is forging a new frontier in personalised diabetes management, allowing for treatments uniquely tailored to individual metabolic needs.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.